Skip to Content

New Drug Approvals Archive - May 2015

See also: New Indications and Dosage Forms for May 2015

May 2015

Invega Trinza (paliperidone palmitate) Extended-Release Injectable Suspension

Date of Approval: May 18, 2015
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Schizophrenia

Invega Trinza (3-month paliperidone palmitate) is a long-acting injectable atypical antipsychotic indicated for the treatment of schizophrenia.

Stiolto Respimat (olodaterol and tiotropium) Inhalation Spray

Date of Approval: May 21, 2015
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Treatment for: Chronic Obstructive Pulmonary Disease

Stiolto Respimat (olodaterol and tiotropium bromide) is a long-acting beta agonist (LABA) and long-acting muscarinic antagonist (LAMA) fixed-dose combination for the treatment of chronic obstructive pulmonary disease (COPD).

Viberzi (eluxadoline) Tablets

Date of Approval: May 27, 2015
Company: Allergan, Inc.
Treatment for: Irritable Bowel Syndrome

Viberzi (eluxadoline) is a mu-opioid receptor agonist indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.